Gilead sciences, inc. (GILD)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07
Operating Activities:
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest

5,364

5,460

4,644

13,488

18,106

12,059

3,057

2,574

2,789

2,889

2,625

1,970

1,575

Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation expense

255

226

233

177

161

125

103

83

72

67

64

51

36

Amortization expense

1,149

1,203

1,053

981

937

925

242

195

230

198

148

103

64

Purchased in-process research and development expense

-

-

-

-

-

-

-

-

-

-

-

10

0

Stock-based compensation expense

636

845

638

380

382

360

252

209

192

200

180

153

184

In-Process Research and Development Impairment Expense

-

-

-

-

-

-

-

-

-

136

0

-

-

Excess tax benefits from stock-based compensation

-

-

-

-

-

482

279

114

40

81

80

191

76

Tax benefits from exercise and vesting of stock-based awards

-

-

-

-

-

484

285

113

37

82

88

209

110

Deferred income taxes

2,098

-289

82

119

393

236

98

39

-64

-12

42

-24

113

Net unrealized loss (gain) from equity securities

1,241

115

0

-

-

-

-

-

-

-

-

-

-

Up-front and milestone expense related to collaborative and other arrangements

4,346

0

0

-

-

-

-

-

-

-

-

-

-

In-process research and development impairment

800

820

0

432

0

0

-

-

26

-

-

-

-

Write-downs for slow moving and excess raw material and work in process inventory

547

440

0

0

-

-

-

-

-

-

-

-

-

Change in fair value of contingent consideration

-

-

-

-

-

-

-

69

8

-

-

-

-

Other

-184

-171

-304

-162

-562

101

105

-3

47

-10

64

-11

-8

Changes in operating assets and liabilities:
Accounts receivable, net

218

-480

-754

-1,192

1,397

2,578

315

-198

375

348

356

257

138

Inventories

95

310

253

488

855

-143

343

350

200

161

75

330

34

Prepaid expenses and other

307

-903

-358

520

90

371

170

129

13

70

65

-9

252

Accounts payable

-61

-39

-430

47

226

-289

-98

117

428

-4

203

312

-77

Income taxes payable

272

-1,459

5,497

1,010

269

533

30

-68

110

-185

166

-23

76

Accrued liabilities and other

-389

-514

-818

305

3,342

2,013

312

317

292

120

109

136

80

Deferred revenues

-

-

-

-

-

31

22

23

-29

-29

48

25

13

Net cash provided by operating activities

9,144

8,400

11,898

17,047

21,250

12,818

3,105

3,195

3,639

2,833

3,080

2,143

1,669

Investing Activities:
Purchases of marketable debt securities

30,455

10,233

23,314

25,619

17,239

2,107

257

1,245

5,127

5,502

2,614

3,273

3,502

Proceeds from sales of marketable debt securities

7,523

1,522

10,440

13,039

4,792

807

494

528

8,649

3,033

1,440

3,026

2,134

Proceeds from maturities of marketable debt securities

22,398

24,336

7,821

1,700

719

52

78

45

788

683

435

193

195

Up-front and milestone payments related to collaborative and other arrangements

4,301

0

0

-

-

-

-

-

-

-

-

-

-

Purchases of equity securities

1,773

156

0

357

0

18

0

25

0

0

-

-

5

Acquisitions, net of cash acquired

0

0

10,426

0

0

-

379

10,752

588

91

1,247

10

46

Capital expenditures

825

924

590

748

747

557

190

397

131

61

230

115

78

Other

384

190

0

-

-

-

-

-

-

-

-

-

-

Net cash used in investing activities

-7,817

14,355

-16,069

-11,985

-12,475

-1,823

-254

-11,846

3,589

-1,937

-2,215

-178

-1,302

Financing Activities:
Proceeds from debt financing, net of issuance costs

0

0

8,985

5,293

9,902

7,932

0

2,144

4,660

2,962

-

-

-

Proceeds from convertible note hedges

-

-

-

956

784

2,543

2,774

214

36

-

-

-

-

Purchases of convertible note hedges

-

-

-

-

-

26

0

0

-

0

-

-

-

Proceeds from issuances of convertible notes, net of issuance costs

-

-

-

-

-

-

-

-

-

-

0

-

-

Proceeds from Sale of Warrants

-

-

-

-

-

-

-

-

-

155

0

-

-

Proceeds from issuances of senior notes, net of issuance costs

-

-

-

-

-

-

-

-

-

-

0

-

-

Proceeds from issuances of common stock

209

289

234

208

319

331

313

466

211

221

222

246

243

Purchases of convertible note hedges

-

-

-

-

-

-

-

-

-

362

0

-

-

Proceeds from credit facilities, net of issuance costs

-

-

-

-

-

-

-

-

-

-

400

-

0

Repayments of Credit Facility

-

-

-

-

-

-

-

-

-

-

400

-

0

Repurchases of common stock

1,749

2,900

954

11,001

10,002

5,349

582

667

2,383

4,022

998

1,969

487

Repayments of debt and other obligations

2,750

6,250

1,811

1,981

997

4,779

4,440

1,839

686

500

-

-

-

Payments to settle warrants

-

-

-

469

3,865

4,093

1,040

0

0

-

-

-

-

Extinguishment of long-term debt

-

-

-

-

-

-

-

-

-

-

305

-

0

Repayments of other long-term obligations

-

-

-

-

-

-

-

-

1

5

5

4

99

Excess tax benefits from stock-based compensation

-

-

-

-

-

482

279

114

40

81

80

191

76

Payment of contingent consideration

-

-

-

-

-

101

0

0

-

-

-

-

-

Payments of dividends

3,222

2,971

2,731

2,455

1,874

0

0

-

-

-

-

-

-

Other

-122

-486

-330

-276

-151

-

-

-

-

-

-

-

-

Contributions from (distribution to) noncontrolling interest

-

-

-

-

-

35

152

131

-115

131

-44

61

96

Net cash used in financing activities

-7,634

-12,318

3,393

-9,725

-5,884

-3,025

-2,544

563

1,763

-1,338

-1,051

-1,474

-170

Effect of exchange rate changes on cash and cash equivalents

-2

-85

137

41

-67

-56

2

8

-16

77

0

1

-43

Net change in cash and cash equivalents

-6,309

10,352

-641

-4,622

2,824

7,914

309

-8,080

8,975

-365

-186

491

152

Supplemental disclosure of cash flow information:
Interest paid, net of amounts capitalized

982

1,070

1,038

885

529

330

238

249

62

15

8

7

7

Income taxes paid

1,793

3,198

3,342

2,436

3,137

2,060

1,051

1,101

621

1,129

746

495

565